Taprostene (also known as CG 4203), a stable prostacyclin (PGI2) analog was developed by Gruenenthal as a selective agonist of the prostanoid receptor IP1. Taprostene was studied in a clinical trial in patients with acute myocardial infarction, where it was shown that the drug could be a useful adjuvant to thrombolytic agents in acute myocardial infarction. In addition, taprostene participated in a clinical trial for the treatment of critical limb ischemia, where the drug was safe and effective. Besides taprostene was studied in patients with advanced peripheral arterial disease. However, further development of the drug was discontinued.

Terutroban (S18886), a specific thromboxane A2 receptor antagonist, which improves endothelial function and has an antiatherosclerotic effect. The compound is under development by Servier for the potential treatment of cardiovascular diseases and coronary artery disease. In addition, it participated in phase III clinical trials PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack), but this study was stopped, and the result was not achieved.

Imitrodast is thianaphthene derivative and thromboxane A2 inhibitor patented by Japanese pharmaceutical company Sankyo Co as antithrombotic agent.

LEMIDOSUL is a loop diuretic, antihypertensive agent.

OXAZIDIONE was developed as an anticoagulant that could prevent the formation of clots in thromboembolic disease. However, this drug has never been marketed.

Nafagrel [DP 1904, SR 96325] is a thromboxane A2 synthetase inhibitor that was undergoing clinical trials with Daiichi Seiyaku, now Daiichi Pharmaceutical, for the diabetic angiopathies, lupus nephritis and Raynaud's disease in Japan. However the development of Nafagrel has been discontinued.

Etabenzarone is an anti-inflammatory and anticoagulant agent.

Butafosfan is a phosphororganic supplement that is given, most commonly with cyanocobalamin, to cattle, swine, horses, and poultry for the prevention or treatment of phosphorus deficiencies. Butafosfan also plays a vital role in hepatic carbohydrate metabolism. In addition, butafosfan has been regarded as an antistress agent in combination with vitamin B12. Studies with butafosfan in different animals have shown that it improved general health status by stimulating feed intake, immune system, and digestive function. Butafosfan has been reported for the treatment of metabolic disorders caused by stress or nutrition problems in various species.

Diarbarone is the anticoagulant.

Rocepafant (also known as BN 50730 or LAU 8080) is a hetrazepinic derivative and a platelet-activating factor (PAF) receptor antagonist. PAF is a mediator of cerebral ischemic injury and administration of rocepafant in neonatal rats was found to have a neuroprotective role, attenuating hypoxic-ischemic brain injury in neonatal rats. Combined with two other types of compounds, rocepafant was shown to modulate the stress-induced up-regulation of cycloooxygenase-2 and prostaglandin E2 in humans, which may be of potential therapeutic value in the design of treatment for complex neuroinflammatory disorders. This compound has been evaluated for treatment of asthma, arrhytmias and rheumatic disorders, but development of rocepafant has been discontinued in 2003.